Biogen Inc. (BIIB) Earnings Call Transcript & Summary
April 22, 2020
Earnings Call Speaker Segments
Joe Mara
executiveHello, everyone, and thanks for joining us for Biogen's earnings call for the first quarter of 2020. To get started, please head over to the Investors area of biogen.com, where you'll find our earnings release along with the associated financial tables — this includes a reconciliation between GAAP and non-GAAP financial measures that we'll be talking about today. Tables 1 and 2 contain our GAAP financials, while Table 3 provides a reconciliation of our GAAP to non-GAAP financial results; in our view, non-GAAP financial results give a better picture of the ongoing economics of our business and show how we manage things internally. Slides are also available on our website, and they track the discussion for this call. I want to note that forward-looking statements will be made, and those rest on our current expectations and beliefs; such statements carry certain risks and uncertainties, and our actual results could differ materially. For more detail, please review the risk factors covered in our SEC filings; joining me today are our Chief Executive Officer, Michel Vounatsos; Dr. Al Sandrock, EVP, Research and Development; and our CFO, Jeff Capello. I'll now hand things over to Michel.
Michel Vounatsos
executiveHello, everyone, and thanks for being here today. First off, I want to recognize how difficult the worldwide COVID-19 outbreak has made things for a great many individuals. We feel deeply for all those who've been touched by it. We commend the efforts of our staff and people throughout the whole health care sector as they tear down obstacles and collaborate in tackling this pandemic, and we're dedicated to playing our role in assisting communities across the globe. Simultaneously, we're dedicated to drawing lessons from what's happening now and striving to create inventive new ways of operating, for instance by speeding up our digital abilities, which we think will put Biogen in a stronger position going forward. Throughout this difficult and extraordinary period, Biogen's mission and purpose stay unchanged. More than 0.5 million patients globally count on us right now for vital medicines treating serious illnesses, and there's still a pressing need to create novel treatments for the millions of patients enduring crippling disorders of the nervous system. Now let me give you an update on the way we're running our operations during this pandemic. To begin, I'd like to acknowledge how resilient and adaptable the Biogen team has been. Biogen has experienced this worldwide crisis's painful effects firsthand, since a large number of our staff fell ill in the early days and others have been hit since then. We've been lucky that, as of today, every one of our employees has gotten better or is getting better. The majority of those affected among our staff have kept working and carrying out their responsibilities; we're thankful to public health officials for everything they've accomplished, and we're also appreciative of the bravery and empathy shown by the health care professionals who've assisted us and keep helping so many others. We acted in several ways early on to aid our stakeholders and society broadly, among them pledging $10 million from the Biogen Foundation toward worldwide response initiatives; starting a consortium alongside Broad Institute of MIT and Harvard and Partners HealthCare to create and share a biobank and offering Biogen staff members who've recovered, plus those close to them, the chance to give samples and medical information; carrying out a process development and manufacturing partnership with Vir Biotech, which is working on possible antibody treatments for COVID-19; supplying medical equipment and supplies to Partners HealthCare in Massachusetts and creating and donating 3D-printed personal protective equipment in Massachusetts and North Carolina; reaching out to investigators who might wish to assess whether our interferon therapies or our anti-TNF biosimilars could work against COVID-19; making it easier for our medically trained staff to volunteer as health care workers on the front lines and for other staff to volunteer in the community; and putting policies and practices in place to protect our employees and communities, such as having nearly all staff work from home at this point. Those are our first commitments, and we'll keep seeking further ways to assist. Meanwhile, we've stayed sharply concentrated on running the company so that every patient and stakeholder need is met. Watching the Biogen team show agility makes me proud — they moved fast to define creative ways both to reduce risks and to spot fresh opportunities throughout R&D, manufacturing, medical and commercial operations. Allow me to walk you through where things stand in a number of important parts of our business. Right now, our worldwide supply chain is performing well. Our manufacturing sites keep running, we're collaborating with partners throughout the supply chain to preserve continuity, and we keep watching the changing situation closely; we are thoughtfully weighing recent regulatory direction about running clinical trials amid the pandemic, and keeping participants safe in our clinical programs comes first for us. To help lessen the effect on our clinical trials, we're taking inventive steps, for example remote monitoring, remote patient visits and backing home infusions. Even though there could be some impact on schedules for particular clinical trials, the key point is that we continue to expect nearly all of the ten remaining data readouts we recently called attention to will occur prior to the close of 2021. Our communication with regulatory agencies has remained consistent, and that includes aducanumab. We have restructured how our commercial and medical affairs teams function and accelerated the pace of our digital interactions with customers. Working alongside regulators, we are enabling TYSABRI infusions to be given at home when it makes sense. Up to this point, both our operations and our financial results have remained solid, and we believe we're in a good spot to keep our leadership position in neuroscience. That confidence comes from the strength of our core business segments, a sound balance sheet and financial standing, and a strong pipeline spanning multiple major disease areas. We continue to see numerous chances to create substantial value in the near term as we work toward building a portfolio made up of multiple franchises in areas including Alzheimer's, ALS, stroke, ophthalmology and lupus. Now I'd like to move on to the first quarter's key points, beginning with our financials. Revenues for the first quarter rose 1%, reaching $3.5 billion. GAAP earnings per share for the first quarter climbed 13% to $8.08, while non-GAAP EPS increased 31% to $9.14. Now, about how we're doing on our strategic priorities. To start, we've moved ahead nicely on the U.S. regulatory submission for aducanumab. Our talks with the U.S. FDA have stayed productive. At this point our BLA is open, and module submissions have begun. We've taken part in further formal exchanges through channels like Type C meetings, and right now we're getting ready for a pre-BLA meeting set for this summer. Once that's done, we anticipate wrapping up the filing in Q3. I want to express appreciation to the FDA and to the group at Biogen working on aducanumab, who have adapted to operating during the present situation involving COVID 19, especially since certain members of that Biogen group were personally affected. Outside of the United States, preliminary discussions regarding aducanumab have started with regulators in Europe and Japan, although those exchanges are still at an early point. In March, the first patient was dosed in the EMBARK redosing study, which aims to provide eligible patients who participated in our prior aducanumab clinical trials with access to the drug. While we are collecting important data from this study, our position is that it is not required for the filing. On the manufacturing side, we presently anticipate having enough supply to satisfy expected demand for aducanumab, starting with our RTP, North Carolina facility, which will subsequently be supplemented by the large, next-generation, state-of-the-art plant under construction in Solothurn, Switzerland. Building work there is finished, and validation is proceeding as planned. We anticipate it will be up and running before this year ends and that it will generate a portion of commercial aducanumab supply in mid-2021. Taken as a whole, alongside our collaboration partner Eisai, we stay optimistic about the possibility of launching aducanumab as the first therapy capable of reducing clinical decline in Alzheimer's disease, and we keep moving forward on market preparation and launch readiness, with the U.S. as our initial focus.
Michel Vounatsos
executiveWe're hopeful that aducanumab represents the start of a new period of possible therapies for Alzheimer's disease, and our goal is to establish a wide-ranging franchise spanning various targets and modalities. That covers BAN2401, on which we're working together with Eisai, several tau-focused programs; our partnership with CAMP4 aimed at finding novel druggable targets; our purchase of a CK1 inhibitor from Pfizer as a possible symptomatic treatment; plus our fresh alliance with Sangamo for creating gene regulation therapies across a variety of neurological indications, Alzheimer's disease among them. Next, first quarter MS sales, together with OCREVUS royalties, reached $2.3 billion, up 9% compared with the previous year. Globally, the count of patients using our MS products rose 3% year over year, and our business kept showing resilience. We're still rolling out VUMERITY in the U.S. We managed to obtain unrestricted access for VUMERITY more quickly than other recent rival launches; we've also been glad to observe that a substantial share of VUMERITY patients switched from treatments older than TECFIDERA, and roughly 30% of VUMERITY patients haven't had prior therapy; we additionally advanced with our inaugural regulatory submission outside the U.S. for VUMERITY in Israel and intend to seek approval across all major markets globally; we were happy that the U.S. Patent Office upheld the claims of our TECFIDERA patent in a favorable ruling on the IPR challenge; that ruling has been appealed and remains pending. We anticipate a decision from the federal district courts in the Delaware and West Virginia ANDA cases later this year. Moving to the third point, SPINRAZA brought in first quarter worldwide revenues of $565 million, a 9% gain over the previous year and a 4% gain over the preceding quarter. Counting the expanded access program and clinical trials, more than 10,000 patients are receiving SPINRAZA. During this quarter, significant new data were released, demonstrating the clinically meaningful advantage SPINRAZA can provide for teens and adults with SMA, and we started a new trial to assess whether a higher dose of SPINRAZA might yield even better efficacy. Fourth, biosimilars revenue in the first quarter totaled $219 million, reflecting 25% growth year-over-year. We calculate that our biosimilars created roughly EUR 1.8 billion in savings for European health care systems during 2019, and we anticipate that figure will keep rising in 2020; this matters greatly as we strive to open financial headroom for innovation and sustain — and add to the long-term viability of the health care system. Fifth, past Alzheimer's disease, we keep growing and broadening our pipeline. Specifically, during this quarter, we filed a regulatory submission for an intramuscular version of PLEGRIDY in the U.S. and Europe, which could become another valuable choice for MS patients. Sixth, our cash flow production stays robust, and keeps giving us considerable optionality and flexibility for allocating capital. In the first quarter, we produced about $1.5 billion in cash flow from operations. Our ability to assess possible outside business development and M&A opportunities remains intact, backed by financial flexibility and capacity, and we are still active when it comes to BD. As shown previously, our commitment is to maximize shareholder returns while we keep delivering innovative therapies to patients, which calls for a considered approach to every investment we make across both near-term and longer-term horizons. To wrap up, even with the difficulties created by the COVID-19 pandemic, Biogen has kept executing strongly against our strategy. At this point I'll hand the call to Al, who will provide a more detailed update on what we have recently achieved in R&D.
Alfred Sandrock
executiveMichel, thank you — and good morning to all of you. Let me start by taking a moment to express how proud I feel about the manner in which our R&D organization has risen to the challenge of the COVID-19 pandemic. Their resilience, along with their steadfast dedication to patients, truly inspires me. Let me now cover what we've been doing in R&D. In line with the latest regulatory guidance around the world, we've established a set of principles to guide our clinical trial conduct through this extraordinary period. Number one: safeguarding every trial participant along with their health care providers, and preserving the integrity of the data we collect, remains our highest priority. Number two: since our clinical trials are so important to patients battling serious diseases, we aim to continue ongoing trials for as long as the risks to patient and health care provider safety, and to data integrity, can be adequately mitigated. Number three: by and large, we are allowing new patients, sites and countries to enroll in trials that are already underway. Even so, we might stop this for individual studies when that kind of enrollment makes it harder for us to reduce danger to patients and health care providers and to keep data trustworthy; fourth, we might allow new clinical studies to start region by region, as long as risks to safety and data integrity can be sufficiently reduced; even so, we are implementing a limited hold on launching new clinical trials that test molecules that weaken the immune system or specifically alter antiviral responses, with another look in the next few months; this includes holding off on beginning the planned Phase III trial of the pegylated anti-CD40 ligand Fab in systemic lupus erythematosus with UCB; and fifth, we are reviewing informed consent forms from every study to ensure that possible risks related to traveling to study sites and, when relevant, product-specific dangers of viral infection are clearly emphasized. We're also keeping an eye on how the current environment could impact when our ongoing studies are expected to report. The situation is still changing, but we continue to anticipate that most of the 10 mid-to-late-stage data readouts we mentioned recently will happen before 2021 wraps up. That said, we do expect some among those 10 to slip, and that includes the Phase III trial of BIIB093, also known as IV glibenclamide, in large hemispheric infarction, because that study requires giving BIIB093 in an acute hospital setting. Looking ahead, our top concerns remain keeping patients safe and ensuring data stays reliable. That said, at this point we can't share anything more about when readouts will occur. Michel already touched on this, and we're working on several efforts aimed at reducing any additional disruption to the trials we currently have underway. What those efforts involve is things such as remote patient monitoring, remote data verification, transportation support so patients and staff can reach study sites, a new service that brings our investigational therapies directly to patients, help with at-home infusions, and telemedicine offerings designed to cut down on missed visits and dropouts. On top of that, every trial we're running will get a risk assessment focused specifically on COVID-19, so we can flag the operational and scientific risks unique to each study, figure out the right ways to mitigate them, and stay compliant as regulatory guidance keeps shifting. Remote site monitoring is something we just introduced, and we're pushing to get the rest of these measures in place as quickly as we can; alongside that risk-reduction work for our pipeline, our goal is to clarify — to help clarify the mechanisms behind COVID-19 pathogenesis and speed up development of possible therapeutic solutions. Speaking of which, we announced earlier this month that a consortium is being established to build and share a COVID-19 biobank. Our partners in this effort are the Broad Institute of MIT and Harvard, along with Partners HealthCare, whose membership includes Massachusetts General Hospital and Brigham and Women's Hospital. This biobank will serve to centralize a large set of de-identified samples and medical data while making them simpler to study. The aim is to unlock the biology of COVID-19, link molecular signatures with how the disease presents clinically, and accelerate the search for potential therapies. Many of my Biogen colleagues have been eager to help in some way throughout this pandemic, and we take pride in being a founding member of this consortium. Volunteers from Biogen's workforce who've gotten over COVID-19, plus people close to them, will contribute samples and medical information to the biobank. Then in the prior month, we put our signature on a letter of intent and kicked off a partnership with Vir Biotechnology aimed at accelerating process development and manufacturing for human monoclonal antibodies with the potential to neutralize SARS-CoV-2, the virus responsible for COVID-19. It's a point of pride for us to contribute our extensive know-how and strengths in sophisticated biologics manufacturing to this effort with Vir, which might speed up the creation of treatments in the fight against this epidemic. Finally, given the impact that type 1 interferons show in vitro when it comes to antiviral response, we are having discussions with investigators who may be interested in evaluating what our beta-interferon products might provide for COVID-19 treatment. When everything is considered, Biogen's R&D organization has made significant strides in addressing the extraordinary challenge that COVID-19 represents; our goal is to continue moving our innovative neuroscience pipeline forward while also contributing to the collective knowledge about COVID-19 biology and how potential treatments are progressing. Now let me turn to the progress we achieved throughout our pipeline during the first quarter, starting with Alzheimer's disease and dementia. As Michel mentioned, we continued to make headway toward the regulatory filing for aducanumab in the United States. The BLA modules are in the process of being submitted now, and we anticipate that the filing will be finished during Q3. Earlier this month, at the virtual AD/PD meeting, we gave an encore presentation covering the aducanumab Phase III top line results. This same information had been presented previously at the CTAD annual congress back in December, and one month before that, the first participant received the initial dose in the EMBARK redosing trial. In that study, eligible patients who had enrolled in our prior clinical trials — including people who got aducanumab or placebo — will be titrated up to aducanumab infusions dosed at 10 milligrams per kilogram, administered once every 4 weeks. In addition to aducanumab, we keep moving forward a wide-ranging Alzheimer's disease pipeline, which includes the Phase III trial of BAN2401; BIIB080, a tau-targeted antisense oligonucleotide that is in Phase I; plus BIIB076, an anti-tau antibody also in Phase I; along with gosuranemab, a separate anti-tau antibody sitting in Phase II. Now shifting to neuromuscular disorders. During the prior month, an independent observational cohort study that looked at how safe and effective SPINRAZA is among 139 teens and adults living with SMA appeared in Lancet Neurology, which makes it the biggest study of SPINRAZA in teens and adults so far. Unlike what the natural history of SMA would suggest, this real-world study discovered that being treated with SPINRAZA was tied to statistically significant gains in total Hammersmith scores relative to baseline after 6, 10 and 14 months of treatment. Notably, a clinically meaningful improvement — which is defined as at least a 3-point rise in the Hammersmith score — showed up in 40% of patients when assessed at 14 months. No fresh safety issues came to light, and no serious adverse events got reported; once more, these findings highlight the durable efficacy along with the well-established longer-term safety profile of SPINRAZA across a broad range of SMA patients, adults included.
Alfred Sandrock
executiveDuring the previous month, we gave the initial dose to a patient in DEVOTE, which is a Phase II/III trial looking at whether larger amounts of SPINRAZA could deliver still better results than the dose approved at present. The rationale for this trial came from SPINRAZA's well-defined safety profile plus our PK/PD findings indicating that patients whose CSF levels of SPINRAZA are higher experience bigger gains on CHOP INTEND scores and motor milestones; additionally, during the same month, we filed an IND for BIIB105, an antisense oligonucleotide aimed at ataxin-2 for sporadic ALS. The FDA has now examined that IND and judged it acceptable to move forward. This program excites us in particular because it addresses the 90% of ALS patients whose disease is sporadic. Trinucleotide repeat expansions within the ataxin-2 gene have been linked both to a greater likelihood of developing ALS and to faster progression of the disease among those individuals. Critically, ataxin-2 was first discovered as a modifier of TDP-43 toxicity, a pathology found in more than 90% of the ALS population, which implies that lowering ataxin-2 might have therapeutic benefit for sporadic ALS patients. Turning to what we have achieved in MS and neuroimmunology. Among patients with relapsing forms of MS, PLEGRIDY continues to be a handy therapeutic choice possessing a well-established safety and efficacy profile. Nevertheless, tolerability, which includes reactions at the injection site, has been the number one reason patients stop treatment. At the ACTRIMS meeting held in February, we shared data examining whether giving PLEGRIDY intramuscularly could lower injection site reactions relative to subcutaneous administration while preserving bioequivalence. For the primary end point, bioequivalence was demonstrated between the 2 routes of administration on plasma exposures. We additionally discovered that the share of patients reporting injection site reactions dropped by more than 50% following intramuscular dosing versus subcutaneous dosing. We have filed regulatory submissions for an intramuscular version of PLEGRIDY in both the United States and the EU. In March, the FDA revised the labels of AVONEX and PLEGRIDY to add data that help health care providers when they consider use during pregnancy. This comes after label changes in Europe last year that eliminated the contraindication for use during pregnancy; these label modifications matter greatly, since women receive an MS diagnosis at least 2 to 3 more often than men, and women are frequently affected during their childbearing years; we recently obtained top line data from OPUS, a randomized Phase II study, investigating the efficacy, safety and tolerability of natalizumab as an adjunctive therapy in patients with drug-resistant focal epilepsy; however, the primary end point was not achieved, and so we have chosen to halt development of natalizumab in drug-resistant focal epilepsy. Last month, data from the Phase I/II dose escalation study of BIIB112, our AAV-based gene therapy targeting X-linked retinitis pigmentosa, or XLRP, appeared in Nature Medicine. Taken as a whole, findings from this study showed an acceptable safety profile and dose responsive gains in visual function, with 7 of 18 patients having early increases in central retinal sensitivity that persisted at month 6 of follow-up. On the business development side, we shared news not long ago about a wide-ranging partnership with Sangamo Therapeutics, aimed at making use of their exclusive zinc finger protein platform. Thanks to this technology, designer DNA-binding proteins can be produced that are simple to insert into an AAV vector, acting as highly targeted, powerful and adjustable controllers of gene expression. This partnership also gives us entry to Sangamo's capsid engineering platform, which holds the promise to potentially — which holds the promise of finding new capsids so that AAV payloads can be delivered to the central nervous system more efficiently and specifically. Our initial emphasis will be on programs targeting Alzheimer's disease, Parkinson's disease and a third neuromuscular disease target, alongside exclusive rights to as many as 9 further neurological targets. All told, we stay unwavering in our pursuit of creating new treatments for terrible neurological conditions, and our team's quick adaptability during this pandemic fills me with pride. My outlook is hopeful that we will navigate these difficulties, lessen any possible effects on our programs and keep advancing our pipeline. At this point I'll hand the call over to Jeff.
Jeff Capello
executiveThank you, Al, and good morning to all of you. Before I get into my remarks regarding the financial results, I'd like to point out that in our view, the basics of this business remain solid, and our positioning is favorable. The therapies we provide matter greatly to patients who are dealing with severe illnesses. Our operating processes are robust, which lets us run things efficiently even during these difficult periods. We also take pride in how well we perform on the commercial side. On top of that, our financial capitalization is solid; nevertheless, these are times unlike any we've seen, and they will affect our business. I'll now go through the financial results, pointing out the different elements so you can get a feel for how we did, and afterward I'll close with some thoughts on what lies ahead. Let me begin with revenues. For the first quarter, total revenues rose 1% compared with the same period a year earlier, reaching roughly $3.5 billion. It's worth noting that in our view, Q1 got a lift of about $100 million from sales that were pulled forward because of the COVID-19 pandemic, mostly in Europe. As a reminder, Q1 2019 had a benefit of roughly $200 million in other revenues from selling hemophilia inventory to Bioverativ. On the whole, we performed nicely in our MS business, posting revenues of about $2.3 billion during this year's first quarter, which includes OCREVUS royalties of roughly $162 million, up 9% from a year ago. Global MS revenues during Q1 2020 rose 7% compared with the prior year when OCREVUS royalties are excluded. U.S. MS revenues, leaving out OCREVUS, went up 4%, or $58 million, against the prior year. U.S. MS revenues during Q1 2020 took a hit from a channel inventory reduction of about $115 million, versus a reduction of roughly $170 million during Q1 2019. We figure we gained $54 million in extra sales because the quarter had more shipping days, and about half of that affected the quarterly inventory change. Beyond that, we think a net $15 million in sales benefit came our way from COVID-19, with TECFIDERA mainly affected. Beyond the U.S., MS revenues climbed 11%, or $77 million, on greater volumes, with almost no pricing effect and an estimated favorable COVID-19 impact of $59 million, mostly divided between TECFIDERA and interferon. First quarter fumarate revenues worldwide, which cover TECFIDERA and VUMERITY, rose 10% against the prior year, fueled by revenue gains both inside and outside the U.S. Within the U.S., fumarate revenue increased 8%, or $16 million, against the prior year. U.S. fumarate revenues felt the effect of a channel inventory reduction of roughly $85 million during the first quarter of 2020, versus a reduction of about $110 million in Q1 2019. Compared with the prior year, demand for TECFIDERA was favorable, which in our view stems mainly from the additional shipping days and the COVID-19 impact, while underlying performance stayed roughly flat once those effects are removed. Following an initial channel load during Q4, VUMERITY recorded $2 million in U.S. sales during the first quarter of 2020, and our progress in locking down access and reimbursement is going well. On the U.S. side, we felt good about how well we executed, and our share of total prescriptions for the fumarates held steady compared with the previous quarter despite tougher competition. One thing worth flagging: when it comes to TECFIDERA and VUMERITY in the U.S., the overwhelming majority of prescriptions go out through mail order. Because of that, we're not anticipating any meaningful hit to TECFIDERA from COVID-19. Turning to markets outside the U.S., TECFIDERA once again did very well — Q1 2020 revenues were up 15%, or $42 million, and that figure includes an estimated benefit of roughly $28 million stemming from inventory dynamics tied to COVID-19. Importantly, patient numbers for TECFIDERA outside the U.S. rose by about 13% compared with the prior year, and that was driven by positive patient growth across the big European markets plus roughly 40% patient growth in Latin America and Asia Pacific combined. All told, we were happy to see TECFIDERA deliver strong global patient growth of about 8% year-over-year. Q1 global interferon revenues, which take in both AVONEX and PLEGRIDY, fell 7% against Q1 2019, reflecting the ongoing shift away from the injectable platforms toward oral or high efficacy therapies; here in the U.S., interferon revenues dropped 11%, or $35 million, versus the prior year. Within the U.S., AVONEX and PLEGRIDY felt the effects of that continued transition to oral and high efficacy therapies, along with a channel inventory decrease of approximately $35 million, compared with a decrease of approximately $15 million in Q1 2019, which was partly affected by the extra shipping days. Just like TECFIDERA, the overwhelming majority of interferon prescriptions in the U.S. go out through mail order. Outside the U.S., interferon revenues held steady versus the prior year, with an estimated benefit of roughly $21 million from increased channel inventory related to COVID-19. Given their safety profile and potential antiviral properties, interest in our interferon products is picking up, which could mean less erosion in this franchise down the road. That's a dynamic we'll be watching closely as time goes on. TYSABRI worldwide revenues climbed 13%, or $62 million, against the first quarter of 2019. In the U.S., TYSABRI revenues rose 13% versus the prior year, or $33 million. U.S. TYSABRI revenues were affected by a channel inventory increase of approximately $5 million, compared with a decrease of approximately $10 million in Q1 2019. Within the U.S., we were pleased to see roughly stable adjusted volumes and share of new prescriptions, plus a higher share of total prescriptions for TYSABRI versus the previous quarter. Outside the U.S., TYSABRI revenues were up 14%, or $29 million, versus the prior year, with an estimated benefit of approximately $7 million from increased channel inventory related to COVID-19. Q1 2020 TYSABRI revenues got a benefit of approximately $20 million from a pricing adjustment in Italy related to prior periods. Outside the U.S., we're pleased to see TYSABRI continue growing patients at 4% versus the prior year. Since TYSABRI gets given in a hospital or at a physician's office, we do anticipate COVID-19 will have some effect on TYSABRI sales. To try to reduce that risk, we're working toward making TYSABRI home infusions possible in the U.S. wherever it makes sense. All in all, we felt good about how our MS franchise performed and about the ongoing strength of our MS business during the first quarter. Although our MS trajectory carries some uncertainty because of COVID-19, TYSABRI especially, there are opportunities too, and the resilience of our market-leading franchise keeps us encouraged. Let me turn now to SPINRAZA. Worldwide SPINRAZA revenues for the first quarter rose 9% from the prior year, reaching $565 million. Within the U.S., revenues were up 5% against Q1 2019 and down 3% against Q4 2019. The count of patients on therapy in the U.S. grew 1% relative to the close of the fourth quarter of 2019, mainly driven by an expanding number of adults; we think U.S. SPINRAZA revenues got a benefit of roughly $6 million from COVID-19; beyond that, leading indicators point to what may be a decline in new patient starts, adults in particular, along with a decline in compliance, with both tied to COVID-19.
Jeff Capello
executiveWe know that certain doctors and medical centers are putting off SPINRAZA administrations while they wrestle with tough choices about how to prioritize care during COVID-19, even though we keep striving to make sure patients get this vital therapy and we've observed additional sites resuming operations. Beyond the U.S., SPINRAZA sales rose 12% compared with Q1 2019 and 10% compared with Q4 2019, mainly because of greater penetration throughout every major geography, along with an approximate $5 million boost from higher channel inventory tied to COVID-19. Beyond the U.S., we've likewise observed a modest effect on SPINRAZA demand stemming from COVID-19, and we anticipate this could persist. Keep in mind that last year's first quarter gained from a favorable pricing adjustment worth $14 million in France, which hurt the year-over-year comparison. Altogether, beyond the U.S., commercial SPINRAZA patient counts rose roughly 10% compared with the previous quarter. Wide-ranging growth happened once more throughout every major region, with a growing count of nations contributing as we carry on this highly successful product launch. On the whole, we felt good about SPINRAZA's results in the first quarter. Although we acknowledge there's some unpredictability in its path, because of the COVID-19 pandemic, we continue to think opportunities for expansion remain, thanks to the large number of patients who haven't been treated, including across numerous established and emerging markets. Now let me shift to our biosimilars business, which brought in $219 million this quarter, up 25% compared with the prior year, or $44 million; we estimate roughly 215,000 patients are now using our biosimilars across Europe. BENEPALI stays the #1 prescribed Enbrel biosimilar throughout the major EU 5 markets. FLIXABI volume climbed 90% compared with the prior year, and IMRALDI volumes climbed 28% compared with the fourth quarter. Even though our biosimilar business gained roughly $15 million because of COVID-19 during the quarter, this business once again did well and has room to keep expanding, both across Europe and possibly inside the U.S; and other geographies with our additional assets. Total anti-CD20 revenues in Q1 rose 1% compared with the prior year, as higher OCREVUS royalties outweighed lower RITUXAN revenues caused by the recent arrival of biosimilars. Total other revenues in the first quarter fell 63% compared with the prior year, chiefly because of the prior period sale of roughly $200 million of hemophilia inventory to Bioverativ in the first quarter of 2019. Let me now shift to gross margins. Q1 2020 gross margin came in at 87%, better than the 83% from the prior year, thanks to lower contract manufacturing revenue, and held fairly steady compared with the prior quarter. Q1 GAAP and non-GAAP R&D expense each represented 13% of revenue. Keep in mind that R&D expense in the first quarter of 2019 contained roughly $39 million tied to our agreement with Skyhawk, plus approximately $45 million in net closeout costs for the Phase III studies of aducanumab. R&D expense in Q1 2020 was lower partly because of the timing of milestones, which are hard to forecast. Looking ahead to Q2 of 2020, we anticipate reporting R&D expense on both a GAAP and non-GAAP basis of $125 million tied to the licensing payment under our Sangamo collaboration. During Q1, SG&A on a GAAP and non-GAAP basis each came in at 16% of revenue; our expectation remains that SG&A will rise as the year progresses while we build up commercial readiness for aducanumab. Other expense under GAAP for Q1 totaled $120 million, and that figure included $61 million of unrealized investment losses, largely the result of a decline in fair value of the equity stake we hold in Ionis. Non-GAAP other expense for Q1 came to $60 million. For Q1 of this year, our tax rate on both a GAAP and non-GAAP basis stood at roughly 17%; back in the first quarter of 2019, the GAAP effective tax rate we reported reflected a onetime charge tied to the planned divestiture of our manufacturing operations in Hillerød, Denmark, along with greater unrealized gains. During Q1 we bought back about 7.3 million shares, paying an average of $303 apiece, for a total of roughly $2.2 billion. The repurchase program that was authorized in March 2019 is now finished. And at the close of the first quarter, roughly $4.1 billion remained available under the repurchase program authorized in December. That brings us to diluted earnings per share. For the first quarter, GAAP EPS came in at $8.08, up 13% from the prior year, while non-GAAP earnings reached $9.14 per share, a rise of 31% from the prior year. We produced roughly $1.5 billion in net cash flows from operations during Q1; we closed the quarter holding about $4.8 billion in cash and marketable securities along with $6 billion in debt. When we consider the rest of the year, we recognize that these times are unprecedented and uncertainty is significant. Let me now lay out what we do know. Once again we delivered strong operational performance in the first quarter and captured some benefit from sales that were pulled forward in connection with COVID-19. We anticipate a degree of volatility in revenues from one quarter to the next. Some disruptions have begun to emerge, notably for TYSABRI and SPINRAZA, stemming from physician administration and facility capacity constraints, as we have observed certain delays in dosing. We consider our therapies essential for patients, and we are actively working to assist patients in keeping to their dosing schedules; we are likewise attentive to possible macro risks arising from the economic climate and the effect on health care systems, including possible effects on payer mix. At the same time, as we have shown previously, we stay focused on strong commercial execution, which we believe could partly help offset these risks. We could also gain from a possible reduction in competitive pressures across a number of business areas and potentially from renewed interest in our interferon therapies. As a reminder, our policy is to update guidance just once each year in July, and hopefully we will know more by that point. Let me now hand the call back to Michel for his closing comments.
Michel Vounatsos
executiveThanks, Jeff. The way the Biogen team has handled what we're facing right now makes me extremely proud. Everywhere in the world, our people have shown toughness and commitment to pushing our mission forward, along with real care and understanding in wanting to help solve this awful illness. Our business is still going strong; we posted solid financials for Q1, and we've shown flexibility in adjusting lots of parts of how we operate, such as how nearly all of our clinical trials are being run. Though we do expect certain risks to hit our business because of the pandemic, we feel our chances to create value stay very attractive, since there's such major unmet medical need in the conditions we're going after. With a robust core business across MS, SMA and biosimilars, we feel the groundwork is there to keep growing a portfolio of multiple franchises. We feel nearly all of our 10 data readouts are still set to wrap up by the close of 2021. On a key note, we've moved along well with the aducanumab filing, and we're busy getting set for a possible commercial launch since we're preparing to spearhead the battle against Alzheimer's disease. Last, let me restate our dedication to boosting returns for shareholders and delivering new treatments to patients over time. That calls for us to keep putting capital to work in ways that are efficient, effective and suitable. As shown previously, we'll always work toward an ideal capital structure and seek outstanding returns on what we invest. How we're handling the present circumstances shows our wider purpose as a company as we seek to break new ground in science for the good of humanity. That means acting rightly toward patients, staff, the planet and the community, and we think all of that feeds into lasting shareholder value over time. Biogen's values make me proud, and I think this path puts us in a strong spot to be a lasting organization well into the future as we stay set on leading in neuroscience to meet the huge societal demands in this area. Now, more than at any other time, I want to express gratitude to our staff worldwide who work hard to improve patients' lives, and to every health care worker on the front lines fighting COVID-19. It has genuinely struck me how the whole health care community has risen to meet these tough times. With that, we'll now take questions.
Marc Goodman
analystRegarding the adu filing, it appears the wording has shifted somewhat in the filing. I suppose everyone was sort of figuring you had submitted or were on the verge of submitting, and now it looks like there was a hold-up. Could you shed a bit more light on what's happening behind the scenes? Is this tied to COVID? Is it a shift in the wording of what you're hearing from FDA? And then as a secondary matter, could you also give us a bit more detail about what you mentioned concerning the interactions in Europe and Japan too?
Michel Vounatsos
executiveThanks for asking that. This is where everyone's attention is focused and it's the top priority inside the organization. Once again, we remain on track, we are getting feedback from the FDA, and our engagement is going very well. I'd say there are 2 primary reasons why it's taking somewhat longer. At the company, we are putting the quality of the submission ahead of the timing. We don't want to hurry and then run into problems. So quality matters, and we must remember that there is an unprecedented dataset plus COVID, alright? The database lock happened in November and it is very complex, with more than 3,200 patients, multiple biomarkers and multiple end points; and when you combine that with severe one, it makes for a complex and unprecedented dataset. So I wanted to lay that out upfront before Al adds to it. Al?
Alfred Sandrock
executiveRight, can everyone hear me? What I'd like to say is this — look, it's tough to forecast when things will land; we've been attempting that from the moment we made the first announcement back in October, and this is not a typical process. Still, I want to stress that an open BLA is now in place. Modules have begun going in; our dialogue with FDA has stayed constructive, and as far as the potential for approval goes, we think we remain on track. On that — I wouldn't take much more away from it. Then regarding the other part of what you asked, which I think concerned Japan as well as Europe, we've begun engaging there too; compared with what's happening with FDA it's fairly early, but a start has been made.
Terence Flynn
analystPerhaps only a quick additional question. I was simply curious whether you could let us know if the FDA has requested any further analyses of the aducanumab data? And then Michel and Al, I'd just be interested to hear, if your degree of confidence in the dataset is equal today to what it was when you declared your plan to submit for approval last year?
Michel Vounatsos
executiveSo the confidence level stays the same. Al will handle the remainder of the question.
Alfred Sandrock
executiveYeah. I'd say analyses are something we do all the time, but honestly nothing has really shifted when it comes to — the data hasn't surfaced anything that alters how we read it. The way we see the fundamentals is the same; and I want to stress that we're still engaged in a constructive way. The reason for these extra Type C meetings is really to deepen our engagement with FDA, which is what we've done right from the start — in fact, it goes back to last June, when our first Type C meeting took place.
Umer Raffat
analystMichel, one quick thing for you, and then one for Al. Michel, you've been talking repeatedly about strong movement on the aducanumab description, yet it appears you may now require a pre-BLA meeting, and that didn't seem to be the situation before. So could you say more about that? And Al, it looks like — I'm merely trying to read between the lines of your remarks, and it appears you're needing to conduct extra analyses, and maybe those are why more meetings with FDA are taking place. And I suppose what I'm asking is, has FDA given you feedback before regarding how you handled imputations for non-completers, because you may remember, the reason EMERGE succeeded at the high dose was that the effect size among completers was presumed to match that among non-completers; and also the entire matter of whether FDA would want you to pull the data — has FDA provided feedback? We aren't asking what that feedback is, but has FDA given that feedback to you?
Michel Vounatsos
executiveUmer, when we last had the chance to talk, there was no open BLA; we had nothing filed with the FDA. So there has been solid movement. We held further Type C meetings, and you should take from this that the FDA has strong interest. So this is what we keep characterizing as positive progress. Al?
Alfred Sandrock
executiveUmer, what I'd say is this: a pre-BLA meeting with FDA was something we'd intended all along, and that's still the case. It was part of the plan from the start. And listen, COVID did hit some folks on the team, and I can tell you that working while you have COVID is tough. The exhaustion — both mental and physical — meant that certain individuals were laid up by the illness, so I think that plays a role here. That said, I'd argue the bulk of it comes down to this — the key thing is that nothing in the data has emerged that alters how we read it; EMERGE, in our view, is a positive study. It came out positive on the prespecified primary endpoint and on all 3 secondary end points. I mean, we've run analyses on ENGAGE to try to understand why that result came out differently. But our belief is that the fundamentals haven't changed and the potential for approval hasn't changed either, just as Michel has said right from the start.
Michel Vounatsos
executiveAnd if something will have changed, we will communicate so.
Ronny Gal
analystSadly, we likely need to — let's keep going with aducanumab as our topic. I suppose there are two parts to my question. The first: has the data prompted any fresh questions? Of course, we're all aware of certain concerns you've heard previously and the way you responded to them. Yet basically, when you consider this, and given that the FDA has an approved BLA in hand and may have data access — have any previously unasked questions come up because of this? And secondly, ought we to anticipate that you'll share additional aducanumab data at some point in this year? Any further analysis you plan to show us prior to when the FDA review actually becomes visible to us?
Alfred Sandrock
executiveRonny, Al here. Truly, nothing new has come up. The — like I mentioned before, regarding the data, we have not found anything that genuinely alters how we read the data. So I'd put it this way: at the core, there aren't major shifts and there aren't new questions. I'd add too that our intention is not to make any further public presentations right now, until — with luck, until approval. That said, that's what we intend.
Phil Nadeau
analystOnce more, staying on the aducanumab topic, I suppose this is a two-part question. First, going back yet again to what's different now. During the Q4 call, it seemed as though you stated back then that the only thing left was submitting some documents, and nothing was said about further Type C meetings or approved BLA meetings. So I suppose, were all of us wrong that those meetings were still necessary and had always been intended, or did something arise, again, essentially the same question, that created the need for those meetings? And then second, I believe what all of us are attempting to hash out here is, what is the FDA's level of interest in aducanumab. I'm aware you mentioned there's a high level of interest, but might you give us a clearer picture of how the FDA currently views the data and whether you can tell if there's disagreement inside the FDA regarding the quality of the results.
Michel Vounatsos
executiveAl?
Alfred Sandrock
executivePhil, what I'd like to convey is that this has been a rather out-of-the-ordinary procedure. It differs from anything I've ever encountered across my 22 years with Biogen. So — and from the outset, the character of this procedure has involved working together, starting with that initial Type C meeting; so I'd describe it as an extremely collaborative effort. And then, sure, filing documents sounds straightforward, yet the BLA is quite intricate. It contains numerous sections and numerous modules. And so although assembling a submission may sound simple, I can tell you it isn't; and I believe that — and predicting the schedule has proven hard, in part since it's been an atypical procedure from day one. And we've always — honestly, we've been holding Type C meetings since last June, and that hasn't shifted; in fact, the reality that we're conducting Type C meetings has remained constant from the start. So those are the key takeaways.
Michael Yee
analystAlso, in case nobody has mentioned this yet, I hope all of you are staying very safe. We're all aware of how severely this has struck, and everybody within the financial community is grateful for that. My question, I believe, is directed at Al — you brought up the pre-BLA meeting, and I realize it's approaching. Could you perhaps discuss which kinds of topics or main questions would get covered during it? And can we safely assume that further subgroup analyses, for instance APOE positive compared with negative, plus geographic variations, those sorts of analyses are already finished and form part of this entire package?
Alfred Sandrock
executiveWell, what I'd say is that geographic matters, subgroup analyses — that's routine for each and every BLA I've ever had a hand in. As a matter of fact, certain sections of them exist that require examining data across different geographies. So that isn't any different from any other BLA I've ever had a hand in. During a standard pre-BLA meeting, what you do is go through — it's closer to an operational sort of meeting. Different sections of the FDA will be taking part in reviewing the BLA, so you sit down together and discuss the way it will be submitted, precisely what will be submitted, and you reach some agreement regarding the operational elements of the submission itself. That's what a standard pre-BLA meeting looks like.
Jay Olson
analystIt's wonderful to hear everyone is doing fine, and I'd like to praise the efforts you're making in the battle against COVID-19. I have a question, perhaps one with a somewhat longer horizon, regarding aducanumab. As you start thinking about giving TYSABRI through home infusion, does that lay the groundwork for possibly delivering aducanumab via infusions at home? Also, would Biogen staff handle that, or would you bring in an outside company for it?
Alfred Sandrock
executiveWell, administering intravenous medications at home has existed for many decades. Back when I was in practice, I myself prescribed certain drugs for home infusion, so this isn't unusual. As for whether aducanumab will be given that way, we haven't revealed that yet, but imagining it wouldn't be hard. It's extremely well — the infusions themselves are tolerated extremely well. So picturing that happening after approval wouldn't be hard.
Michel Vounatsos
executiveThat said, bringing a product to market once COVID has passed strikes me as something quite worthwhile to evaluate — going past what we'd call the ordinary state of affairs we're getting set for across numerous fronts, our capacity to connect outside of digital means, in person, the way we draw people in, plus infusion and a great deal else. On this, we're making preparations. Two forces are at play. The first involves overseeing the trajectory of a product that's firmly entrenched, which is precisely our focus, and we're handling it extremely well. The second is that introducing something new while COVID is around poses difficulties; after COVID, whether that works remains something we still have to gauge.
Evan Seigerman
analystActually, aducanumab isn't what I'll be asking about. There's something else I want to bring up. Yesterday, an appellate court issued a ruling concerning the 001 patent for TECFIDERA, which points toward a possible launch of the Banner monomethyl fumarate. How should we read into that decision? And suppose you were to lose one or both of the district court cases coming up regarding TECFIDERA — what would you do to safeguard the franchise?
Jeff Capello
executiveEvan, it's Jeff here. The Banner product isn't a directly substitutable A/B product. That's the first point I'd stress as important. Should it launch, our view is there won't be a meaningful impact right now; then as far as the 2 court cases go, clearly we were quite happy to receive the favorable IPR ruling. That marks the third occasion that patent has held up. Our sense is that our patent position is fairly strong; even so, should we not prevail in either of the 2 district court cases, we have — VUMERITY is something we can view as a fumarate strategy we're pursuing. There are growth opportunities for us worldwide, with even fairly strong results beyond the U.S; we believe SMA holds solid growth potential, BBU too. And naturally, the aducanumab potential is there as well. So we will — my view is the franchise is fairly strong, and we'll grow around it.
Cory Kasimov
analystSo, turning back to aducanumab, I’d like to get a clearer picture of what it means to send in modules for your BLA ahead of holding that pre-BLA meeting. Was this — I mean, was a rolling BLA submission always the case? Was that the plan from the start? I’m just attempting to grasp the significance, and with this pre-BLA meeting, we didn’t think it would be needed as of the last call?
Alfred Sandrock
executiveYes. Cory, this is Al. The common technical document consists of several modules. There are, for instance, quality modules tied to the manufacturing process, there are nonclinical parts, and then there are the clinical parts, which finish with a clinical overview, which is — so there are summary documents covering the actual study reports from individual clinical studies. Those are the 3 primary sections. As you can picture, the nonclinical portion was already more or less set, since little has changed there — non-clinically speaking, since the early days, though we still needed to assemble the actual documentation and so on; so those make up the sections of the common technical document. All of them get submitted electronically. And so — and look, we had — beginning around October or so, we did begin to consider sending modules in as they were ready. That was our intention. But a pre-BLA meeting remains fairly standard practice, as I mentioned, so that both parties, Biogen and FDA, can be — can reach alignment on the operational elements of the CTD. So I wouldn’t take much from that. As I said, we intended to hold that meeting right from the start.
Joe Mara
executiveWe probably have time for about 2 more questions.
Matthew Harrison
analystI apologize for returning to aducanumab, but the remarks you've made this morning are really hard for me to make sense of. So I was hoping you might address just one particular point. I believe your earlier guidance indicated a filing would come in early 2020, and now you're referring to a 3Q filing, which strikes me as a considerable delay, and yet the way you describe it suggests nothing has shifted and that essentially all your expectations remain on track. So there appears to be a real mismatch between the timeline and what you're saying. And I'm just hoping you can perhaps take a moment to walk us through what has occurred?
Alfred Sandrock
executiveFrom the very start, our aim was to try to give an estimate, a timing for this filing ever since the announcement in October, actually. But timing is never simple to forecast; and as I mentioned earlier, in fact, this process is not a usual one. So predicting timing becomes even more difficult when the process itself is quite unusual and, based on my experience, one of a kind. I'd simply say that the constructive engagement has existed from the very start, and it carries on. These Type C meetings are formal channels for engaging with FDA. A pre-BLA meeting is yet another formal meeting with FDA to keep moving along the road toward approval; we have an open BLA. And yes, there's a — we stated early 2020, so at this point it's Q3; COVID did have some effect on us. But overall, I'd say that what we're telling you is that the potential for approval, we remain on track for that.
Carter Gould
analystPerhaps a somewhat different angle on the aducanumab matter. Clearly, during the quarter we received gantenerumab data along with DIAN-TU data. Al, could you possibly share your view regarding how appropriate it is to extrapolate from the absence of cognitive benefit in that trial over to aducanumab? And has this information in any way altered the discussions being held with the FDA?
Alfred Sandrock
executiveThank you, Carter. To begin with, I'd like to congratulate Randy Bateman along with every investigator involved in DIAN-TU. In my view, it's a lovely study. Conducting it is quite difficult since, even though the population is homogeneous in the sense that all of them suffer from autosomal dominant Alzheimer's disease from a genetic and biological standpoint, it's fairly heterogeneous clinically — they might be 2 decades, 1 decade, or just a few years away from developing symptoms. So how do you combine data drawn from that clinically heterogeneous group? Furthermore, it's a comparatively small trial; roughly 50 patients in each arm, as I recall. Thus DIAN-TU examined both solanezumab and gantenerumab. Solanezumab produced no alteration in amyloid PET according to imaging, and there was no effect whatsoever. So that isn't particularly surprising. Gantenerumab, though, did produce an impact on amyloid PET. Nevertheless, I'd like to contrast how large the effect was for gantenerumab versus aducanumab, and really the sole method for doing so is employing the Centiloid scale. The entire rationale behind Centiloid was that it was created to allow comparisons across studies, given that different PET ligands are used and different reference regions are employed to derive the SUVR score. Within the PRIME study, 10 milligrams per kilogram of aducanumab corresponded to a shift on the Centiloid scale of roughly 57 over 1 year. Within the DIAN-TU study, gantenerumab corresponded to a shift from baseline of roughly 14 Centiloid units across 4 years. So I'd say that's fairly distinct. What we aimed to convey at the CTAD meeting is that dosage is significant and that how robustly amyloid is removed is significant; we observed that in the data, and I believe we presented it. So in certain respects, when I consider the DIAN-TU data, I feel it somewhat affirms what we've been stating — that you must achieve high doses and robust amyloid clearance before any clinical benefit becomes apparent.
Joe Mara
executiveI'll turn it over to Michel for some closing comments.
Michel Vounatsos
executiveThanks, everyone, for joining us today. I want to note that despite being personally impacted by this awful pandemic, Biogen is showing remarkable resilience. The company stands even stronger at present, and we're set up well for what lies ahead — beginning with aducanumab, while also anticipating all the key readouts over the upcoming stretch.
Joe Mara
executiveThank you, everybody.
Operator
operatorThanks for joining us, everyone. That wraps up the call for today. You're free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.